Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230797 | 0.85 | ATM (0.66) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3232737 | 0.83 | LMNA (0.58) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3260363 | 0.82 | ALDH1A1 (0.56) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3264356 | 0.82 | KDM4E (0.56) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3641005 | 0.82 | MEN1 (0.60) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3233391 | 0.80 | MEN1 (0.71) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3382792 | 0.80 | ALDH1A1 (0.54) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3226304 | 0.79 | KDM4E (0.56) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL13492900 | 0.79 | MEN1 (0.52) | MAPTLMNARAB9ANPC1MEN1 | |
| SCHEMBL3235282 | 0.79 | MTNR1A (0.69) | MAPTLMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010012397-A1 | N-(INDOL-3-YLALKYL)(HETERO)ARYLAMIDE DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | claimed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | claimed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | claimed |
| WO-2010012397-A1 | N-(INDOL-3-YLALKYL)(HETERO)ARYLAMIDE DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012397-A1 | N-(INDOL-3-YLALKYL)(HETERO)ARYLAMIDE DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | PTGER2, PTGER1, PTGDR2 | MAPT 4374/4885LMNA 1855/4885RAB9A 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.